CIK 0001703057 · Large accelerated filer
AbCellera Biologics Inc.
Sign in to watch- Ticker
- ABCL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (604) 559-9005
- Business address
- 150 W 4TH AVENUE, VANCOUVER, British Columbia, Canada, V5Y 1G6
- Open-market buys, last 90 days
- $1,379,662
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$1,379,662. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-09 | Hansen Carl L. G. Chief Executive Officer | Sale | −5,598,420 | $24.03 | $134.5M | 55,604,330 |
| 2021-06-09 | Hansen Carl L. G. Chief Executive Officer | Sale | −401,580 | $25.50 | $10.2M | 233,500 |
| 2021-06-09 | Lecault Veronique Chief Operating Officer | Sale | −1,000,000 | $25.50 | $25.5M | 273,630 |
| 2021-06-09 | Stimart Tryn Chief Legal Officer | Sale | −1,000,000 | $25.50 | $25.5M | 250 |
| 2021-06-09 | Booth Andrew Chief Financial Officer | Sale | −1,200,000 | $25.50 | $30.6M | 0 |
| 2021-06-09 | Falconer Ester Chief Technology Officer | Sale | −1,000,000 | $25.50 | $25.5M | 0 |
| 2021-06-07 | Stimart Tryn Chief Legal Officer | Option exercise | +750,000 | $0.32 | $240K | 750,250 |
| 2021-06-07 | Stimart Tryn Chief Legal Officer | Option exercise | +250,000 | $2.30 | $575K | 1,000,250 |
| 2021-06-07 | Stimart Tryn Chief Legal Officer | Option exercise · Share Option (right to buy) | −750,000 | 1,250,000 | ||
| 2021-06-07 | Stimart Tryn Chief Legal Officer | Option exercise · Share Option (right to buy) | −250,000 | 600,000 | ||
| 2021-06-07 | Booth Andrew Chief Financial Officer | Option exercise | +600,000 | $0.19 | $114K | 600,000 |
| 2021-06-07 | Booth Andrew Chief Financial Officer | Option exercise | +600,000 | $0.32 | $192K | 1,200,000 |
| 2021-06-07 | Booth Andrew Chief Financial Officer | Option exercise · Share Option (right to buy) | −600,000 | 300,000 | ||
| 2021-06-07 | Booth Andrew Chief Financial Officer | Option exercise · Share Option (right to buy) | −600,000 | 4,950,000 | ||
| 2021-03-19 | Falconer Ester Chief Technology Officer | Option exercise | +1,000,000 | $0.03 | $34K | 1,000,000 |
| 2021-03-19 | Falconer Ester Chief Technology Officer | Option exercise · Share Option (right to buy) | −1,000,000 | 0 | ||
| 2020-12-15 | DCVC Bio, L.P. 10% owner | Conversion | +29,076,350 | 29,076,350 | ||
| 2020-12-15 | DCVC Bio, L.P. 10% owner | Conversion | +29,411 | 29,105,761 | ||
| 2020-12-15 | DCVC Bio, L.P. 10% owner | Conversion · Series A1 Preferred Shares | −2,105,264 | 0 | ||
| 2020-12-15 | DCVC Bio, L.P. 10% owner | Conversion · Series A2 Preferred Shares | −802,371 | 0 |
Page 8 of 11 · 203 trades